Oscar Tahuahua, Medical Oncology fellow at National Institute of Cancerology, shared a post on X:
“Neoadjuvant Aumolertinib in stage III EGFR+ NSCLC: Ph2 trial
110 mg QD for 16 weeks
ORR: 70.6%
Surgery: 45.1% | R0: 100%
MPR: 21.7% | pCR: 13%
Ex19-Del vs L858R → ORR: 91 vs 59%, MPR: 44 vs 7%
Promising neoadj strategy, esp. in Ex19Del tumors.”
